“…However, many of these interventions are directed at molecules and processes that are also required in normal cells, resulting in significant toxicity. We have shown that dominant-negative peptides derived from the RNA-binding domains of hnRNPU and RBM39 (also known as CAPERα) have minimal effects on normal cells because they disrupt cancer-cell-specific interactions and molecular functions 42 , 43 and may have significant clinical advantages over less targeted approaches. Here, we provide support for further exploration and development of a peptide with dominant-negative functions in hnRNPK, called CPP-hnRNPK-RGG, as a therapeutic peptide.…”